Neurologic Manifestations
59
7
9
36
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
6.8%
4 terminated out of 59 trials
90.0%
+3.4% vs benchmark
5%
3 trials in Phase 3/4
6%
2 of 36 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 36 completed trials
Clinical Trials (59)
Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions
Rett Syndrome Registry
Functional Skills Training for Supermarket Shopping Using NFC Technology in People With Intellectual Disabilities
Multimodal Intervention in Patients With Non-specific Chronic Low Back Pain: the HEALTHY BACK Project
A Feasibility Study on the Safety and Preliminary Efficacy of Bilateral Subthalamotomy Using MRgFUS for Treatment of PD
The Effects of Dexmedetomidine on Postoperative Cognitive Function in Open Heart Surgery
Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits
Hypersensitivity to Amylin in Post-Traumatic Headache
Amylin-Induced Migraine Attacks Without Aura
Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients
Acute Transcranial Direct Current Stimulation in Patients With Systemic Autoimmune Myopathies
Predictive and Advanced Analytics in Emergency Medicine - Neurological Deficits
Dopaminergic Therapy for Frontotemporal Dementia Patients
Extension Study to Study PQ-110-001 (NCT03140969)
Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
A Decade-Long Dance With Diplopia: Unraveling the Enigma of Recurrent 6th Nerve Palsy
The Afolabi Stroke Registry for Children and Young Adults With SCD in Northern Nigeria
NUMITOR Study: Nummular Headache Iberian Study on the Treatments and Outcomes in Real-World Setting
Psychological Support Group and Its Effects on Mood, Anxiety and Coping
Cohort of Patients With Covid-19 Presenting Neurological or Psychiatric Disorders (CoCo-Neurosciences)